KRAS and carcinoma: In conclusion, Kras mutation appears to be one of the imperative events in the ovarian mucinous adenoma–borderline tumor–carcinoma sequence, as increased numbers of Kras mutations have been shown to be the strongest predictor of unequivocal malignancy in ovarian mucinous neoplasms.